Next Article in Journal
Effect of Fucoidan Extracted from Mozuku on Experimental Cartilaginous Tissue Injury
Next Article in Special Issue
Characterization and Cytotoxicity Studies of the Rare 21:4 n-7 Acid and Other Polyunsaturated Fatty Acids from the Marine Opisthobranch Scaphander lignarius, Isolated Using Bioassay Guided Fractionation
Previous Article in Journal
Paralytic Toxins Accumulation and Tissue Expression of α-Amylase and Lipase Genes in the Pacific Oyster Crassostrea gigas Fed with the Neurotoxic Dinoflagellate Alexandrium catenella
Previous Article in Special Issue
Clinical Trial: Marine Lipid Suppositories as Laxatives
Mar. Drugs 2012, 10(11), 2535-2559; doi:10.3390/md10112535
Review

Distinguishing Health Benefits of Eicosapentaenoic and Docosahexaenoic Acids

*  and
Received: 24 September 2012; in revised form: 16 October 2012 / Accepted: 31 October 2012 / Published: 13 November 2012
(This article belongs to the Special Issue Marine Lipids)
View Full-Text   |   Download PDF [300 KB, uploaded 13 November 2012]   |   Browse Figure
Abstract: Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) are recommended for management of patients with wide-ranging chronic diseases, including coronary heart disease, rheumatoid arthritis, dementia, and depression. Increased consumption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is recommended by many health authorities to prevent (up to 0.5 g/day) or treat chronic disease (1.0 g/day for coronary heart disease; 1.2–4 g/day for elevated triglyceride levels). Recommendations for dietary intake of LC n-3 PUFAs are often provided for α-linolenic acid, and for the combination of EPA and DHA. However, many studies have also reported differential effects of EPA, DHA and their metabolites in the clinic and at the laboratory bench. The aim of this article is to review studies that have identified divergent responses to EPA and DHA, and to explore reasons for these differences. In particular, we review potential contributing factors such as differential membrane incorporation, modulation of gene expression, activation of signaling pathways and metabolite formation. We suggest that there may be future opportunity to refine recommendations for intake of individual LC n-3 PUFAs.
Keywords: LC n-3 PUFAs; omega-3 fatty acids; eicosapentaenoic acid; docosahexaenoic acid; resolvin D1; differential response; omega-3 fatty acid metabolites LC n-3 PUFAs; omega-3 fatty acids; eicosapentaenoic acid; docosahexaenoic acid; resolvin D1; differential response; omega-3 fatty acid metabolites
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Russell, F.D.; Bürgin-Maunder, C.S. Distinguishing Health Benefits of Eicosapentaenoic and Docosahexaenoic Acids. Mar. Drugs 2012, 10, 2535-2559.

AMA Style

Russell FD, Bürgin-Maunder CS. Distinguishing Health Benefits of Eicosapentaenoic and Docosahexaenoic Acids. Marine Drugs. 2012; 10(11):2535-2559.

Chicago/Turabian Style

Russell, Fraser D.; Bürgin-Maunder, Corinna S. 2012. "Distinguishing Health Benefits of Eicosapentaenoic and Docosahexaenoic Acids." Mar. Drugs 10, no. 11: 2535-2559.


Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert